219 related articles for article (PubMed ID: 10528790)
1. Fusidic acid in bone and joint infections.
Atkins B; Gottlieb T
Int J Antimicrob Agents; 1999 Aug; 12 Suppl 2():S79-93. PubMed ID: 10528790
[TBL] [Abstract][Full Text] [Related]
2. Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus.
Wang JL; Tang HJ; Hsieh PH; Chiu FY; Chen YH; Chang MC; Huang CT; Liu CP; Lau YJ; Hwang KP; Ko WC; Wang CT; Liu CY; Liu CL; Hsueh PR
Int J Antimicrob Agents; 2012 Aug; 40(2):103-7. PubMed ID: 22612900
[TBL] [Abstract][Full Text] [Related]
3. Community-acquired methicillin-resistant Staphylococcus aureus in bone and joint infections: development of rifampicin resistance.
Donaldson AD; Chan RC; Gosbell IB
Med J Aust; 2006 Feb; 184(4):196. PubMed ID: 16489910
[No Abstract] [Full Text] [Related]
4. [Teicoplanin in the treatment of bone and joint infections due to methicillin resistant staphylococci. Experience in adult patients].
Pensotti C; Nacinovich F; Vidiella G; Carbone E; Marin M; Di Stéfano C; Stamboulian D
Medicina (B Aires); 2002; 62 Suppl 2():40-7. PubMed ID: 12481488
[TBL] [Abstract][Full Text] [Related]
5. Fusidic acid in staphylococcal bone and joint infection.
Coombs RR
J Antimicrob Chemother; 1990 Feb; 25 Suppl B():53-60. PubMed ID: 2179204
[TBL] [Abstract][Full Text] [Related]
6. Failure of combination therapy for Staphylococcus aureus bone infection: a case of in vivo selection with resistance to rifampicin and fusidic acid.
Aubin GG; Bémer P; Guillouzouic A; Launay E; Geffroy L; Touchais S; Corvec S
Infect Dis (Lond); 2016 Sep; 48(9):699-702. PubMed ID: 27194514
[TBL] [Abstract][Full Text] [Related]
7. High usage of topical fusidic acid and rapid clonal expansion of fusidic acid-resistant Staphylococcus aureus: a cautionary tale.
Williamson DA; Monecke S; Heffernan H; Ritchie SR; Roberts SA; Upton A; Thomas MG; Fraser JD
Clin Infect Dis; 2014 Nov; 59(10):1451-4. PubMed ID: 25139961
[TBL] [Abstract][Full Text] [Related]
8. Fusidic acid in the treatment of methicillin-resistant Staphylococcus aureus.
Whitby M
Int J Antimicrob Agents; 1999 Aug; 12 Suppl 2():S67-71. PubMed ID: 10528788
[TBL] [Abstract][Full Text] [Related]
9. [In vitro kinetics of the activity of fusidic acid and fluoroquinolones combinations against staphylococci according to methicillin-resistance phenotype. Implications for the treatment of osteoarticular infections].
Reynaud AE; Espaze EP; Coste-Burel M; Richet H
Pathol Biol (Paris); 1992 May; 40(5):466-70. PubMed ID: 1495828
[TBL] [Abstract][Full Text] [Related]
10. Successful oral pristinamycin therapy for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA) and other Staphylococcus spp.
Ng J; Gosbell IB
J Antimicrob Chemother; 2005 Jun; 55(6):1008-12. PubMed ID: 15845784
[TBL] [Abstract][Full Text] [Related]
11. Clindamycin combination treatment for the treatment of bone and joint infections caused by clindamycin-susceptible, erythromycin-resistant Staphylococcus spp.
Bonnaire A; Vernet-Garnier V; Lebrun D; Bajolet O; Bonnet M; Hentzien M; Ohl X; Diallo S; Bani-Sadr F
Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115225. PubMed ID: 33099073
[TBL] [Abstract][Full Text] [Related]
12. Management of osteoarticular infections caused by Staphylococcus aureus is similar to that of other etiologies: analysis of 199 staphylococcal bone and joint infections.
Pääkkönen M; Kallio PE; Kallio MJ; Peltola H
Pediatr Infect Dis J; 2012 May; 31(5):436-8. PubMed ID: 22189524
[TBL] [Abstract][Full Text] [Related]
13. Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid.
Aboltins CA; Page MA; Buising KL; Jenney AW; Daffy JR; Choong PF; Stanley PA
Clin Microbiol Infect; 2007 Jun; 13(6):586-91. PubMed ID: 17331125
[TBL] [Abstract][Full Text] [Related]
14. Oral fusidic acid fails to eradicate methicillin-resistant Staphylococcus aureus colonization and results in emergence of fusidic acid-resistant strains.
Chang SC; Hsieh SM; Chen ML; Sheng WH; Chen YC
Diagn Microbiol Infect Dis; 2000 Feb; 36(2):131-6. PubMed ID: 10705056
[TBL] [Abstract][Full Text] [Related]
15. Outcome of debridement and retention in prosthetic joint infections by methicillin-resistant staphylococci, with special reference to rifampin and fusidic acid combination therapy.
Peel TN; Buising KL; Dowsey MM; Aboltins CA; Daffy JR; Stanley PA; Choong PF
Antimicrob Agents Chemother; 2013 Jan; 57(1):350-5. PubMed ID: 23114758
[TBL] [Abstract][Full Text] [Related]
16. Teicoplanin-based antimicrobial therapy in Staphylococcus aureus bone and joint infection: tolerance, efficacy and experience with subcutaneous administration.
Peeters O; Ferry T; Ader F; Boibieux A; Braun E; Bouaziz A; Karsenty J; Forestier E; Laurent F; Lustig S; Chidiac C; Valour F;
BMC Infect Dis; 2016 Nov; 16(1):622. PubMed ID: 27809799
[TBL] [Abstract][Full Text] [Related]
17. Safety of antibiotics combinations against Staphylococcal bone and joint infections.
Danré A; Courjon J; Bernard E; Cua E; Mondain V; Roger PM
Joint Bone Spine; 2015 Mar; 82(2):134-5. PubMed ID: 24962979
[No Abstract] [Full Text] [Related]
18. Evaluation of antibiotic resistance to orally administrable antibiotics in staphylococcal bone and joint infections in one of the largest university hospitals in Germany: is there a role for fusidic acid?
Klein S; Nurjadi D; Eigenbrod T; Bode KA
Int J Antimicrob Agents; 2016 Feb; 47(2):155-7. PubMed ID: 26774158
[TBL] [Abstract][Full Text] [Related]
19. Addition of fusidic acid impregnated bone cement to systemic teicoplanin therapy in the treatment of rat osteomyelitis.
Ersoz G; Oztuna V; Coskun B; Eskandari MM; Bayarslan C; Kaya A
J Chemother; 2004 Feb; 16(1):51-5. PubMed ID: 15077999
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of Staphylococcus aureus to fusidic acid: Canadian data.
Rennie RP
J Cutan Med Surg; 2006; 10(6):277-80. PubMed ID: 17241597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
